Evaluation_NN of_IN a_DT New_NP Dot_NP Blot_NP Enzyme_NP Immunoassay_NP (_( Directigen_NP Flu_NP A+B_NP )_) for_IN Simultaneous_NP and_CC Differential_NP Detection_NP of_IN Influenza_NP A_NP and_CC B_NP Virus_NP Antigens_NNS from_IN Respiratory_NP Samples_NP We_PP report_VBP a_DT prospective_JJ evaluation_NN of_IN a_DT new_JJ dot_NN blot_NN enzyme_NN immunoassay_NN (_( EIA_NP )_) method_NN for_IN the_DT direct_JJ ,_, rapid_JJ ,_, qualitative_JJ ,_, simultaneous_JJ ,_, and_CC differential_JJ detection_NN of_IN the_DT influenza_NN A_DT (_( IA_NN )_) and_CC B_NP (_( IB_NP )_) virus_NN antigen_NN in_IN different_JJ respiratory_JJ samples_NNS ._SENT The_DT EIA_NP method_NN was_VBD compared_VBN with_IN the_DT shell_JJ vial_NN culture_NN system_NN (_( MDCK_NP cell_NN line_NN )_) used_VBN with_IN the_DT same_JJ samples_NNS ._SENT We_PP studied_VBD 160_CD samples_NNS from_IN 93_CD (_( 58.1_CD %_NN )_) pediatric_JJ patients_NNS (_( hospital_NN emergency_NN room_NN )_) and_CC from_IN 67_CD (_( 41.9_CD %_NN )_) adult_NN patients_NNS (_( sentinel_NN network_NN )_) ._SENT Seventy-four(46.2%)_JJ samples_NNS were_VBD considered_VBN positive_JJ ;_: of_IN them_PP ,_, 46_CD (_( 62.2_CD %_NN )_) were_VBD from_IN pediatric_JJ patients_NNS and_CC 28_CD (_( 37.8_CD %_NN )_) were_VBD from_IN an_DT adult_JJ group_NN (_( P_NN <_SYM 0.05_CD )_) ,_, with_IN overall_JJ positive_JJ values_NNS of_IN 49.9_CD %_NN and_CC 41.7_CD %_NN ,_, respectively_RB ._SENT All_DT 74_CD (_( 100_CD %_NN )_) of_IN the_DT positive_JJ samples_NNS were_VBD isolated_VBN in_IN cell_NN culture_NN versus_IN the_DT 68.9_CD %_NN that_WDT were_VBD detected_VBN as_IN positive_JJ by_IN the_DT new_JJ EIA_NP method_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT Of_IN the_DT 41_CD samples_NNS positive_JJ for_IN the_DT IA_JJ virus_NN ,_, the_DT EIA_NP detected_VBD 34_CD (_( 82.9_CD %_NN )_) positive_JJ samples_NNS ;_: of_IN the_DT 33_CD samples_NNS positive_JJ for_IN the_DT IB_NP virus_NN ,_, the_DT EIA_NP detected_VBD 17_CD (_( 51.5_CD %_NN )_) positive_JJ samples_NNS (_( P_NN <_SYM 0.05_CD )_) ._SENT No_DT false-positive_JJ reaction_NN was_VBD detected_VBN with_IN the_DT EIA_NP method_NN (_( specificity_NN and_CC positive_JJ predictive_JJ value_NN of_IN 100_CD %_NN )_) ._SENT The_DT overall_JJ results_NNS obtained_VBN in_IN the_DT comparison_NN between_IN the_DT new_JJ EIA_NP and_CC the_DT shell_JJ vial_NN culture_NN had_VBD a_DT sensibility_NN of_IN 82.9_CD %_NN and_CC predictive_JJ negative_JJ values_NNS of_IN 92.4_CD %_NN for_IN the_DT IA_JJ virus_NN and_CC 51.5_CD %_NN and_CC 84.3_CD %_NN ,_, respectively_RB ,_, for_IN the_DT IB_NP virus_NN ._SENT This_DT evaluation_NN shows_VBZ sensitivity_NN and_CC specificity_NN percentages_NNS for_IN the_DT new_JJ EIA_NP method_NN that_WDT is_VBZ acceptable_JJ for_IN routine_JJ use_NN in_IN IA_JJ virus_NN detection_NN ._SENT The_DT results_NNS obtained_VBN were_VBD worse_JJR for_IN IB_NP virus_NN detection_NN ,_, but_CC this_DT new_JJ EIA_NP method_NN is_VBZ actually_RB the_DT only_JJ one_CD with_IN the_DT capacity_NN to_TO differentiate_VB between_IN the_DT two_CD influenza_NN viruses_NNS ._SENT Influenza_NN is_VBZ an_DT infection_NN caused_VBN by_IN the_DT influenza_NN A_NP and_CC B_NP (_( IA_NP and_CC IB_NP )_) viruses_NNS ,_, which_WDT present_VBP as_IN epidemic_JJ outbreaks_NNS in_IN the_DT winter_NN months_NNS ._SENT This_DT epidemiological_JJ fact_NN is_VBZ of_IN use_NN in_IN the_DT clinical_JJ diagnosis_NN of_IN this_DT infection_NN ._SENT Usually_RB ,_, this_DT infection_NN may_MD be_VB considered_VBN self-limiting_VBG in_IN healthy_JJ populations_NNS ._SENT Nevertheless_RB ,_, in_IN the_DT very_RB young_JJ and_CC in_IN immunodepressed_JJ patients_NNS it_PP may_MD lead_VB to_TO an_DT increase_NN in_IN morbidity_NN and_CC mortality_NN ._SENT However_RB ,_, it_PP is_VBZ necessary_JJ to_TO carry_VB out_RP a_DT definitive_JJ etiological_JJ diagnosis_NN at_IN the_DT beginning_NN of_IN ,_, and_CC during_IN ,_, each_DT epidemiological_JJ period_NN in_IN order_NN to_TO establish_VB the_DT prevalence_NN and_CC appearance_NN of_IN new_JJ strains_NNS or_CC subtypes_NNS not_RB included_VBD in_IN the_DT recommended_JJ vaccine_NN ._SENT At_IN the_DT same_JJ time_NN ,_, the_DT appearance_NN and_CC the_DT availability_NN of_IN neuraminidase_NN inhibitors_NNS requires_VBZ a_DT rapid_JJ (_( these_DT new_JJ antivirals_NNS are_VBP most_RBS effective_JJ when_WRB given_VBN within_IN 48_CD h_NN of_IN symptoms_NNS )_) and_CC specific_JJ diagnosis_NN of_IN influenza_NN virus_NN infection_NN ._SENT The_DT diagnosis_NN of_IN influenza_NN infection_NN is_VBZ largely_RB clinical_JJ ,_, but_CC this_DT method_NN has_VBZ been_VBN demonstrated_VBN to_TO be_VB both_DT insensitive_JJ and_CC nonspecific_JJ ._SENT The_DT reference_NN method_NN (_( gold_NN standard_NN )_) for_IN laboratory_NN diagnosis_NN of_IN influenza_NN is_VBZ the_DT isolation_NN of_IN the_DT virus_NN ._SENT This_DT may_MD be_VB carried_VBN out_RP by_IN inoculation_NN in_IN embryonated_JJ hens_NNS '_POS eggs_NNS ,_, in_IN laboratory_NN reference_NN only_RB ,_, or_CC by_IN means_NNS of_IN cell_NN culture_NN (_( classical_JJ or_CC shell_JJ vial_NN type_NN )_) ._SENT These_DT methods_NNS ,_, however_RB ,_, have_VBP serious_JJ drawbacks_NNS in_IN that_WDT they_PP are_VBP slow_JJ and_CC laborious_JJ and_CC require_VB from_IN 2_CD to_TO 7_CD days_NNS to_TO reach_VB the_DT final_JJ result_NN ._SENT Consequently_RB ,_, rapid_JJ techniques_NNS based_VBN on_IN the_DT detection_NN of_IN viral_JJ antigens_NNS or_CC of_IN physiological_JJ viral_JJ activity_NN (_( neuraminidase_NN )_) have_VBP been_VBN developed_VBN ._SENT Immunofluorescence_NP is_VBZ a_DT highly_RB sensitive_JJ and_CC specific_JJ technique_NN ,_, but_CC it_PP requires_VBZ a_DT minimum_JJ number_NN of_IN cells_NNS in_IN the_DT sample_NN and_CC an_DT expert_JJ technician_NN for_IN good_JJ interpretation_NN ._SENT The_DT enzyme_NN immunoassay_NN systems_NNS (_( EIA_NP )_) have_VBP provided_VBN high_JJ sensitivity_NN ,_, high_JJ specificity_NN (_( nucleoprotein_NN as_IN the_DT antigen_NN )_) ,_, rapid_JJ diagnosis_NN (_( less_JJR than_IN 15_CD min_NN )_) ,_, and_CC technical_JJ simplicity_NN ._SENT The_DT majority_NN of_IN these_DT systems_NNS are_VBP performed_VBN on_IN a_DT solid_JJ membrane_NN and_CC are_VBP based_VBN on_IN an_DT enzymatic_JJ reaction_NN with_IN the_DT development_NN of_IN a_DT visual_JJ color_NN ._SENT The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO carry_VB out_RP a_DT prospective_JJ evaluation_NN of_IN a_DT new_JJ EIA_NP method_NN in_IN the_DT direct_JJ ,_, qualitative_JJ ,_, simultaneous_JJ ,_, and_CC differential_JJ detection_NN of_IN the_DT IA_NP and_CC IB_NP virus_NN antigens_NNS in_IN different_JJ clinical_JJ samples_NNS of_IN symptomatic_JJ patients_NNS ._SENT From_IN January_NP to_TO December_NP 2001_CD we_PP evaluated_VBD the_DT efficacy_NN of_IN a_DT new_JJ commercial_JJ rapid_JJ EIA_NP method_NN for_IN the_DT differential_JJ detection_NN of_IN the_DT IA_NN and_CC IB_NN viruses_NNS in_IN clinical_JJ samples_NNS of_IN two_CD different_JJ population_NN groups_NNS ._SENT Samples_NNS were_VBD taken_VBN from_IN adult_NN patients_NNS attended_VBD to_TO in_IN the_DT sentinel_NN network_NN (_( community-based_JJ study_NN )_) by_IN using_VBG a_DT throat_NN swab_NN vigorously_RB rubbed_VBD on_IN both_DT tonsillar_JJ surfaces_NNS and_CC the_DT posterior_JJ pharynx_NN ._SENT In_IN the_DT case_NN of_IN patients_NNS attended_VBD to_TO in_IN the_DT pediatric_JJ emergency_NN room_NN of_IN our_PP$ hospital_NN (_( pediatric_JJ group_NN )_) ,_, a_DT nasopharyngeal_JJ aspirate_NN was_VBD taken_VBN ._SENT Both_DT types_NNS of_IN samples_NNS were_VBD inoculated_VBN in_IN compatible_JJ liquid_JJ transport_NN medium_NN (_( Earle_NP 's_POS minimum_JJ essential_JJ medium_NN with_IN 0.5_CD %_NN bovine_JJ serum_NN albumin_NN )_) for_IN viruses_NNS and_CC sent_VBD as_RB soon_RB as_RB possible_JJ to_TO the_DT virology_NN laboratory_NN ._SENT Each_DT of_IN the_DT samples_NNS was_VBD subjected_VBN to_TO antigen_NN detection_NN against_IN IA_NP and_CC IB_NP viruses_NNS with_IN the_DT new_JJ rapid_JJ differential_JJ EIA_NP membrane_NN test_NN (_( Directigen_NP Flu_NP A+B_NP ;_: Becton_NP &_CC Dickinson_NP Co._NP ,_, Sparks_NP ,_, Md._NP )_) following_VBG the_DT manufacturer_NN 's_POS recommendations_NNS ._SENT At_IN the_DT same_JJ time_NN ,_, each_DT sample_NN was_VBD inoculated_VBN in_IN two_CD shell_JJ vials_NNS of_IN the_DT MDCK_NP cell_NN line_NN (_( Vircell_NP ,_, Granada_NP ,_, Spain_NP )_) ,_, which_WDT were_VBD incubated_VBN for_IN 72_CD h_NN at_IN 36C_JJ ,_, after_IN which_WDT the_DT monolayers_NNS were_VBD stained_VBN with_IN a_DT specific_JJ monoclonal_NN antibody_NN against_IN the_DT IA_JJ (_( clone_NN IA52/9_NN )_) and_CC IB_NP (_( clone_NN IB82/2_NN )_) viruses_NNS (_( Monofluokit_NP Influenza_NP ;_: Sanofi_NP Diagnostics_NP Pasteur_NP ,_, Marnes_NP la_NP Coquette_NP ,_, France_NP )_) by_IN an_DT indirect_JJ immunofluorescence_NN assay_NN ._SENT Statistical_JJ analysis_NN was_VBD carried_VBN out_RP on_IN results_NNS of_IN different_JJ comparisons_NNS by_IN performing_VBG the_DT Student_NN 's_POS t_NN test_NN on_IN paired_VBN data_NNS ._SENT All_DT P_NN values_NNS are_VBP two-tailed_VBN and_CC considered_VBN significant_JJ if_IN they_PP are_VBP less_JJR than_IN 0.05_CD ._SENT In_IN this_DT study_NN we_PP analyzed_VBD 160_CD clinical_JJ samples_NNS from_IN 93_CD (_( 58.1_CD %_NN )_) pediatric_JJ patients_NNS and_CC 67_CD (_( 41.9_CD %_NN )_) patients_NNS of_IN the_DT sentinel_NN network_NN (_( adults_NNS )_) ._SENT Of_IN these_DT samples_NNS ,_, 74_CD (_( 46.2_CD %_NN )_) were_VBD considered_VBN positive_JJ (_( detection_NN and/or_CC viral_JJ isolation_NN )_) ._SENT Of_IN the_DT positive_JJ samples_NNS ,_, 46_CD (_( 62.2_CD %_NN )_) were_VBD from_IN the_DT pediatric_JJ group_NN and_CC 28_CD (_( 37.8_CD %_NN )_) were_VBD from_IN the_DT sentinel_NN group_NN (_( P_NN <_SYM 0.05_CD )_) ,_, giving_VBG an_DT overall_JJ positivity_NN of_IN 49.4_CD %_NN for_IN the_DT pediatric_JJ samples_NNS and_CC 41.7_CD %_NN for_IN the_DT sentinel_NN group_NN ._SENT All_DT 74_CD (_( 100_CD %_NN )_) of_IN the_DT positive_JJ samples_NNS were_VBD isolated_VBN in_IN cell_NN culture_NN ,_, 68.9_CD %_NN of_IN which_WDT were_VBD detected_VBN as_IN positive_JJ by_IN the_DT EIA_NP method_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT The_DT IA_JJ virus_NN was_VBD isolated_VBN in_IN 41_CD samples_NNS (_( 25.6_CD %_NN )_) ,_, and_CC the_DT IB_NP virus_NN was_VBD isolated_VBN in_IN 33_CD (_( 20.6_CD %_NN )_) samples_NNS ._SENT Of_IN the_DT 41_CD samples_NNS positive_JJ for_IN the_DT IA_JJ virus_NN the_DT EIA_NP method_NN detected_VBD 34_CD (_( 82.9_CD %_NN )_) positive_JJ samples_NNS ,_, and_CC of_IN the_DT 33_CD samples_NNS positive_JJ for_IN the_DT IB_NP virus_NN the_DT EIA_NP method_NN detected_VBD 17_CD (_( 51.5_CD %_NN )_) (_( P_NN <_SYM 0.05_CD )_) ._SENT Of_IN the_DT 46_CD positive_JJ pediatric_JJ samples_NNS the_DT IA_NN virus_NN was_VBD isolated_VBN in_IN 30_CD and_CC was_VBD detected_VBN by_IN the_DT EIA_NP method_NN in_IN 26_CD (_( 86.6_CD %_NN )_) ._SENT The_DT IB_NP virus_NN was_VBD isolated_VBN in_IN 16_CD samples_NNS in_IN this_DT group_NN and_CC was_VBD detected_VBN by_IN the_DT EIA_NP method_NN in_IN 10_CD (_( 62.5_CD %_NN )_) ._SENT Of_IN the_DT 28_CD positive_JJ samples_NNS from_IN the_DT sentinel_NN group_NN ,_, the_DT IA_JJ virus_NN was_VBD isolated_VBN in_IN 11_CD samples_NNS and_CC was_VBD detected_VBN by_IN the_DT EIA_NP method_NN in_IN 8_CD (_( 72.7_CD %_NN )_) ._SENT The_DT IB_NP virus_NN was_VBD isolated_VBN in_IN 17_CD samples_NNS in_IN this_DT group_NN and_CC was_VBD detected_VBN by_IN the_DT EIA_NP method_NN in_IN 7_CD (_( 41.1_CD %_NN )_) samples_NNS ._SENT No_DT false-positive_JJ reaction_NN was_VBD detected_VBN with_IN the_DT EIA_NP method_NN studied_VBD ,_, giving_VBG us_PP a_DT specificity_NN and_CC positive_JJ predictive_JJ value_NN of_IN 100_CD %_NN ._SENT Table_NN shows_VBZ the_DT overall_JJ results_NNS and_CC the_DT results_NNS obtained_VBN for_IN each_DT group_NN in_IN the_DT comparison_NN between_IN isolation_NN in_IN cell_NN culture_NN and_CC antigen_NN detection_NN (_( new_JJ EIA_NP method_NN )_) ._SENT TABLE_NN 1_CD |_SYM Results_NNS obtained_VBN from_IN the_DT comparison_NN between_IN shell_JJ vial_NN culture_NN and_CC the_DT rapid_JJ EIA_NP test_NN The_DT new_JJ EIA_NP method_NN examined_VBD in_IN this_DT study_NN is_VBZ rapid_JJ and_CC simple_JJ ,_, and_CC it_PP permits_VBZ the_DT simultaneous_JJ and_CC differential_JJ detection_NN of_IN IA_NP and_CC IB_NP virus_NN antigens_NNS ._SENT The_DT comparison_NN between_IN the_DT cell_NN culture_NN (_( shell_JJ vial_NN )_) and_CC this_DT new_JJ EIA_NP method_NN showed_VBD an_DT overall_JJ sensitivity_NN of_IN 68.9_CD %_NN ,_, somewhat_RB lower_JJR than_IN expected_VBN ._SENT However_RB ,_, if_IN we_PP separate_VBP the_DT two_CD viruses_NNS detected_VBD we_PP find_VBP that_IN the_DT sensitivity_NN for_IN IA_NN was_VBD 82.9_CD %_NN ,_, while_IN for_IN the_DT IB_NP virus_NN it_PP was_VBD 51.5_CD %_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT In_IN a_DT previous_JJ study_NN carried_VBD out_RP with_IN the_DT same_JJ antigen_NN detection_NN EIA_NP method_NN against_IN only_RB the_DT IA_JJ virus_NN (_( Directigen_NP Flu_NP A_NP ;_: Becton_NP &_CC Dickinson_NP )_) ,_, a_DT sensitivity_NN of_IN 84.7_CD %_NN was_VBD observed_VBN ._SENT Therefore_RB ,_, the_DT present_JJ method_NN displays_VBZ a_DT practically_RB identical_JJ behavior_NN against_IN the_DT IA_JJ virus_NN ,_, maintaining_VBG very_RB similar_JJ sensitivity_NN values_NNS ,_, similar_JJ to_TO results_NNS of_IN other_JJ studies_NNS ._SENT One_CD of_IN the_DT advantages_NNS of_IN the_DT new_JJ EIA_NP method_NN is_VBZ the_DT ability_NN to_TO specifically_RB detect_VB the_DT IB_NP virus_NN ._SENT Until_IN now_RB no_DT other_JJ EIA_NP method_NN with_IN this_DT capacity_NN had_VBD been_VBN commercialized_VBN ,_, so_IN there_EX are_VBP no_DT previous_JJ studies_NNS with_IN which_WDT we_PP can_MD compare_VB our_PP$ results_NNS ._SENT Reina_NP et_FW al._FW have_VBP previously_RB reported_VBN a_DT sensitivity_NN of_IN 66.6_CD %_NN for_IN an_DT indirect_JJ immunofluorescence_NN technique_NN against_IN the_DT shell_JJ vial_NN culture_NN in_IN the_DT detection_NN of_IN the_DT IB_NP ._SENT This_DT value_NN is_VBZ slightly_RB higher_JJR than_IN that_DT detected_VBN by_IN the_DT EIA_NP method_NN evaluated_VBN in_IN this_DT study_NN ,_, confirming_VBG the_DT idea_NN that_IN ,_, in_IN general_NN ,_, immunofluorescence_NN techniques_NNS are_VBP usually_RB somewhat_RB more_RBR sensitive_JJ than_IN the_DT EIA_NP methods_NNS for_IN the_DT influenza_NN viruses_NNS ._SENT One_CD of_IN the_DT main_JJ problems_NNS when_WRB evaluating_VBG different_JJ methods_NNS for_IN the_DT antigenic_JJ detection_NN of_IN respiratory_JJ viruses_NNS is_VBZ the_DT type_NN of_IN sample_NN studied_VBD ._SENT For_IN this_DT reason_NN we_PP divided_VBD the_DT patients_NNS into_IN two_CD different_JJ groups_NNS ,_, both_CC for_IN reasons_NNS of_IN age_NN (_( children_NNS and_CC adults_NNS )_) and_CC for_IN the_DT type_NN of_IN clinical_JJ sample_NN analyzed_VBN (_( nasopharyngeal_JJ aspirate_NN and_CC pharyngeal_JJ swab_NN )_) ._SENT The_DT majority_NN of_IN studies_NNS concerning_VBG other_JJ EIA_NP methods_NNS with_IN the_DT ability_NN to_TO detect_VB simultaneously_RB ,_, although_IN not_RB differentially_RB ,_, the_DT IA_NP and_CC IB_NP viruses_NNS have_VBP shown_VBN important_JJ variations_NNS in_IN sensitivity_NN according_VBG to_TO the_DT type_NN of_IN sample_NN studied_VBD ._SENT Thus_RB ,_, in_IN the_DT study_NN of_IN Schultze_NP et_FW al._FW we_PP find_VBP that_IN the_DT optical_JJ immunoassay_NN method_NN (_( Flu_NP OIA_NP )_) displays_VBZ an_DT overall_JJ sensitivity_NN of_IN 71.8_CD %_NN in_IN pediatric_JJ samples_NNS and_CC of_IN 51.4_CD %_NN in_IN adult_JJ samples_NNS ._SENT In_IN the_DT same_JJ way_NN ,_, Covalciuc_NP et_FW al._FW reported_VBD that_IN ,_, with_IN this_DT same_JJ method_NN ,_, the_DT highest_JJS sensitivity_NN is_VBZ obtained_VBN with_IN nasal_JJ aspirate_NN (_( 88.4_CD %_NN )_) ,_, and_CC the_DT lowest_JJS sensitivity_NN is_VBZ obtained_VBN with_IN the_DT throat_NN swab_NN (_( 62.1_CD %_NN )_) ._SENT In_IN our_PP$ study_NN the_DT new_JJ EIA_NP method_NN displayed_VBD a_DT sensitivity_NN of_IN 86.6_CD %_NN for_IN pediatric_JJ samples_NNS and_CC 72.7_CD %_NN for_IN adult_JJ samples_NNS (_( sentinel_NN network_NN )_) in_IN the_DT detection_NN of_IN the_DT IA_JJ virus_NN ._SENT The_DT difference_NN between_IN the_DT two_CD groups_NNS and/or_CC types_NNS of_IN sample_NN was_VBD greater_JJR in_IN the_DT case_NN of_IN IB_NP virus_NN (_( 62.5_CD %_NN versus_IN 41.1_CD %_NN ;_: P_NN <_SYM 0.05_CD )_) ._SENT It_PP seems_VBZ obvious_JJ ,_, once_RB more_JJR ,_, that_IN the_DT type_NN of_IN sample_NN and_CC ,_, therefore_RB ,_, the_DT viral_JJ load_NN present_NN is_VBZ what_WP probably_RB determines_VBZ the_DT sensitivity_NN of_IN the_DT different_JJ antigen_NN detection_NN methods_NNS against_IN the_DT majority_NN of_IN respiratory_JJ viruses_NNS ._SENT This_DT phenomenon_NN does_VBZ not_RB affect_VB the_DT cell_NN culture_NN ,_, which_WDT scarcely_RB displays_VBZ differences_NNS in_IN sensitivity_NN according_VBG to_TO the_DT type_NN of_IN clinical_JJ sample_NN (_( ,_, ,_, ,_, )_) ._SENT Over_IN the_DT study_NN period_NN we_PP found_VBD no_DT false-positive_JJ antigen_NN detection_NN with_IN the_DT new_JJ EIA_NP method_NN ,_, establishing_VBG a_DT specificity_NN and_CC positive_JJ predictive_JJ value_NN of_IN 100_CD %_NN ._SENT Therefore_RB ,_, a_DT positive_JJ result_NN with_IN this_DT method_NN provides_VBZ ,_, with_IN a_DT high_JJ degree_NN of_IN certainty_NN ,_, the_DT diagnosis_NN of_IN infection_NN by_IN the_DT influenza_NN viruses_NNS ._SENT It_PP may_MD be_VB used_VBN as_IN a_DT rapid_JJ screening_NN method_NN for_IN patients_NNS with_IN symptoms_NNS of_IN infection_NN by_IN the_DT influenza_NN viruses_NNS ._SENT A_DT negative_JJ result_NN in_IN the_DT test_NN does_VBZ not_RB exclude_VB the_DT existence_NN of_IN viral_JJ infection_NN ,_, especially_RB for_IN those_DT caused_VBN by_IN the_DT IB_NP virus_NN ._SENT In_IN general_NN ,_, the_DT antigenic_JJ detection_NN methods_NNS for_IN the_DT IB_NP virus_NN have_VBP displayed_VBN lower_JJR sensitivity_NN percentages_NNS ,_, and_CC alternative_JJ methods_NNS ,_, such_JJ as_IN cell_NN culture_NN or_CC reverse_JJ transcription-PCR_NN ,_, should_MD be_VB used_VBN ._SENT The_DT availability_NN of_IN antiviral_JJ drugs_NNS effective_JJ against_IN the_DT IA_NP and_CC IB_NP viruses_NNS justifies_VBZ the_DT need_NN for_IN the_DT rapid_JJ and_CC specific_JJ detection_NN of_IN infection_NN caused_VBN by_IN these_DT viruses_NNS ._SENT In_IN addition_NN ,_, the_DT efficacy_NN of_IN these_DT drugs_NNS is_VBZ maximum_JJ when_WRB they_PP were_VBD used_VBN within_IN the_DT first_JJ 48_CD h_NN of_IN the_DT appearance_NN of_IN the_DT disease_NN ._SENT Therefore_RB ,_, physicians_NNS require_VBP rapid_JJ and_CC simple_JJ diagnostic_JJ methods_NNS which_WDT they_PP themselves_PP can_MD use_VB in_IN their_PP$ consulting_NN rooms_NNS ._SENT However_RB ,_, since_IN sometimes_RB the_DT reading_NN of_IN results_NNS obtained_VBN by_IN EIA_NP methods_NNS can_MD be_VB difficult_JJ ,_, a_DT sample_NN should_MD be_VB always_RB sent_VBN to_TO the_DT laboratory_NN for_IN confirmation_NN ,_, culture_NN ,_, isolation_NN ,_, and_CC typing_VBG the_DT virus_NN for_IN epidemiological_JJ studies_NNS ._SENT In_IN summary_NN ,_, this_DT study_NN shows_VBZ sensitivity_NN and_CC specificity_NN percentages_NNS for_IN the_DT new_JJ EIA_NP method_NN which_WDT is_VBZ acceptable_JJ for_IN routine_JJ use_NN in_IN antigen_NN detection_NN of_IN IA_JJ virus_NN ,_, and_CC it_PP is_VBZ comparable_JJ with_IN other_JJ no-differential_JJ methods_NNS ._SENT The_DT results_NNS obtained_VBN are_VBP worse_JJR for_IN IB_NP antigenic_JJ detection_NN ,_, but_CC this_DT new_JJ EIA_NP is_VBZ actually_RB the_DT only_JJ one_CD with_IN the_DT capacity_NN to_TO differentiate_VB between_IN the_DT two_CD influenza_NN viruses_NNS ._SENT At_IN the_DT same_JJ time_NN ,_, it_PP was_VBD possible_JJ to_TO confirm_VB the_DT variations_NNS in_IN the_DT behavior_NN of_IN this_DT antigenic_JJ method_NN depending_VBG on_IN the_DT sample_NN used_VBD ._SENT It_PP has_VBZ been_VBN shown_VBN to_TO be_VB highly_RB effective_JJ for_IN nasopharyngeal_JJ aspirates_NNS from_IN children_NNS attended_VBD to_TO in_IN hospital_NN emergency_NN rooms_NNS and_CC has_VBZ been_VBN shown_VBN to_TO be_VB somewhat_RB less_RBR effective_JJ for_IN the_DT detection_NN of_IN these_DT viruses_NNS in_IN adult_JJ patients_NNS from_IN the_DT sentinel_NN network_NN ._SENT 